Objectives: Determine predictors of hospitalization and institutionalization in Medicaid populations with Alzheimer’s Disease (AD). Methods: Data were obtained from the Centers for Medicareand Medicaid Services (CMS). Individuals enrolled in Florida,New Jersey, and New York Medicaid programs on January 1, 2004, remained in that program for 1 year and exposed to an AD medication were included. AD diagnosis was based on the ICD-9-CM code 331.0. Outcomes of interest were hospitalization and institutionalization. Multivariate logistic regression models were used to test for the association between outcomes of interest and demographics, resource utilization factors, and type of AD pharmacotherapy exposure. Results: A total of 65,442 individuals qualified for the study. Age was positively and significantly associated with hospitalization (p < 0.001) and institutionalization (p < 0.001). Exposure tomemantine was significantly associated with less chance of hospitalization (OR = 0.88; 99% CI: 0.77 - 0.99). Non-Hispanic Blacks were significantly (p < 0.001) more likely to be hospitalized than Non-Hispanic Whites (OR = 1.60; 99% CI: 1.41 - 1.81). Compared to Non-Hispanic Whites, Non-Hispanic Blacks (OR = 0.73; 99% CI: 0.60 - 0.88), Hispanics (OR = 0.36; 99% CI: 0.27 - 0.47), and Non-Hispanic Others (OR = 0.42; 99% CI: 0.21 - 0.82) were significantly less likely to be institutionalized. Individuals prescribed donepezil (OR = 1.29, 99% CI, 1.08 - 1.54) and galantamine (OR = 1.46, 99% CI: 1.19 - 1.79) were significantly more likely to have an institutionalization claim (p < 0.001 for both medications). Residents of New York were significantly morelikely to be hospitalized than Florida residents (OR = 1.30; 99% CI: 1.17 - 1.44), where as New Jersey residents were significantly less likely to be hospitalized (OR = 0.75; 99% CI: 0.66 - 0.85). Finally, compared toFloridaresidents, residents of New Jerseywere significantly more likely to be institutionalized (OR = 4.61; 99% CI: 3.98 - 5.33). Conclusion: Demographics, state of residence and pharmacotherapy exposure weresignificant predictors of health care service utilization. Further pharmacoeconomic studies in AD medication therapy are warranted.
Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A. and Evans, D.A. (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Archives of Neurology, 60, 1119-1122.
The Lewin Group (2010) Lewin Model on Alzheimer’s and dementia and costs. The model estimates total payments for community-based health care services using data from the Medicare Current Beneficiary Survey (MCBS). www.alz.org/trajectory.
Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L. and Farlow, M. (1998) Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials. Dementia trialists’ collaboration. Journal of the American Medical Association, 280, 1777-1782.
Pouryamout, L., Dams, J., Wasem, J., Dodel, R. and Neumann, A. (2012) Economic evaluation of treatment options in patients with Alzheimer’s disease: A systematic review of cost-effectiveness analyses. Drugs, 72, 789- 802. doi:10.2165/11631830-000000000-00000
Jencks, S.F., Cuerdon, T., Burwen, D.R., Fleming, B., Houck, P.M., Kussmaul, A.E., et al. (2000) Quality of medical care delivered to medicare beneficiaries: A profile at state and national levels. Journal of the American Medical Association, 284, 1670-1676.
McGlynn, E.A., Asch, S.M., Adams, J., Keesey, J., Hicks, J., DeCristofaro, A., et al. (2003) The quality of health care delivered to adults in the United States. The New England Journal of Medicine, 348, 2635-2645.
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.C., et al. (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care, 43, 1130-1139.
Charlson, M.E., Pompei, P., Ales, K.L. and MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40, 373-383.
Yang, Z., Zhang, K., Lin, P.J., Clevenger, C. and Atherly, A.A. (2012) Longitudinal analysis of the lifetime cost of dementia. Health Services Research; 47(4): 1660-1678.
Schulz, R., Belle, S.H., Czaja, S.J., McGinnis, K.A., Stevens, A. and Zhang, S. (2004) Longterm care placement of dementia patients and caregiver health and well-being. Journal of the American Medical Association, 292, 961-967. doi:10.1001/jama.292.8.961
McClendon, M.J., Smyth, K.A. and Neundorfer, M.M. (2006) Long-term-care placement and survival of persons with Alzheimer’s disease. Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 61, P220- P227. doi:10.1093/geronb/61.4.P220
The Robert Wood Johnson Foundation (2005) Changes in Medicaid physician fees, 1998-2003: Implications for physician participation.
O’Brien, E. (2005) Long-term care: Understanding Medi- caid’s role for the elderly and disabled. The Kaiser Com- mission on Medicaid and the Uninsured.
Fossett, J.W. and Burke, C.E. (2010) Medicaid policy and long-term care spending. Health Policy Research Center. The Nelson A. Rock-efeller Institute of Government, University at Albany State University of New York.
Cappell, J., Herrmann, N., Cornish, S. and Lanctot, K.L. (2010) The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs, 24, 909-927. doi:10.2165/11539530-000000000-00000
Gilligan, A.M., Malone, D.C., Warholak, T.L. and Armstrong, E.P. (2012) Health disparities in cost of care in patients with Alzheimer’s disease: An analysis across 4 state Medicaid populations. American Journal of Alzheimer’s Disease and Other Dementias, 28, 84-92.
Kruse, R.L., Mehr, D.R., Boles, K.E., Lave, J.R., Binder, E.F., Madsen, R., et al. (2004) Does hospitalization impact survival after lower respiratory infection in nursing home residents? Medical Care, 42, 860-870.
Loeb. M., Carusone, S. C., Goeree, R., Walter, S.D., Brazil, K., Krueger, P., et al. (2006) Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: A randomized controlled trial. Journal of the American Medical Association, 295, 2503-2510.
Beusterien, K.M., Thomas, S.K., Gause, D., Kimel, M., Arcona, S. and Mirski, D. (2004) Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs, 18, 1143-1148.
Knopman, D., Schneider, L., Davis, K., Talwalker, S., Smith, F., Hoover, T., et al. (1996) Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, tacrine study group. Neurology, 47, 166-177. doi:10.1212/WNL.47.1.166